SMC is proud to announce that GN Corporation Co. Ltd (JPN) has published the results of their study using our STAM™ model in BMJ Open Gastroenterology.

In this study, the authors observed how two β-glucans derived from the AFO-202 and N-163 strains of black yeast, Aureobasidium pullulans, affected the gut microbiota and fecal metabolome profile in the STAM™ model.　The results of this study suggest that β-glucans could potentially be used as adjuvants in managing NASH.

Title:

Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease

(Preethy et al., BMJ Open Gastroenterol. 2022)

In a previous study, the authors also evaluated how these β-glucans affected the progression of NASH in the STAM™ model (click here for more details).

In that study, it was found that AFO-202 β-glucan suppressed the development of fatty liver and hepatocyte ballooning, and N-163 strain β-glucan suppressed inflammation and fibrosis, indicating that the inclusion of these two β-glucans into a regular diet could be an effective treatment for NASH.

Recently, there have been increasingly more discussions around the roll that diet and supplements play in improving NASH.

Here at SMC, we have experience conducting efficacy studies not only with compounds, but also supplements and other similar products.

Our STAM™ model is a NASH mouse model with a high clinical correlation that is validated via the NAFLD activity score.

Please feel free to contact us if you are interested in running a study in our STAM™ model, or if you would just like to learn more about the services we offer here at SMC Laboratories.